Management of Concurrent Dengue and HIV Infection

Immediate Assessment and Management

• The Centers for Disease Control and Prevention recommends checking CD4 count immediately upon presentation, as management intensity and risk stratification depend critically on the degree of immunosuppression 1, 2
• Patients with CD4 <200 cells/mm³ require more intensive monitoring and are at higher risk for severe dengue complications 1
• Obtain HIV viral load to assess virologic control, as uncontrolled HIV replication may worsen dengue outcomes 2

Antiretroviral Therapy Management

• The World Health Organization recommends not discontinuing antiretroviral therapy during acute dengue infection, as immune reconstitution is the most important factor in preventing severe complications 3
• If the patient is not on ART, initiate therapy once dengue is stabilized, though timing should be individualized based on CD4 count and clinical status 3

Drug Interactions and Toxicity

• The National Institutes of Health recommends evaluating all medications for potential drug-drug interactions, particularly if the patient requires additional supportive medications 4, 5
• Avoid hepatotoxic medications when possible, as both dengue and some antiretrovirals can cause transaminase elevations 6

HIV-Specific Considerations

• The American Academy of HIV Medicine recommends continuing PCP prophylaxis if CD4 <200 cells/mm³ throughout dengue illness 3
• Maintain antiviral prophylaxis (acyclovir or valacyclovir) if the patient has history of HSV or VZV and CD4 <200 cells/mm³ 3

Disposition and Follow-Up

• The Infectious Diseases Society of America recommends admitting all patients with CD4 <200 cells/mm³ regardless of dengue severity, given higher risk of complications 1
• Recheck CD4 count and HIV viral load 2-4 weeks after dengue resolution to assess for any impact on HIV control 2